NVN Liquidation Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Scott Plesha

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	1.6yrs
Board average tenure	no data

Recent management updates

Recent updates

CEO

Scott Plesha (58 yo)

less than a year

Tenure

Mr. Scott M. Plesha is Chief Executive Officer of Ligand Pharmaceuticals Incorporated from April 2024. Mr. Plesha had been the President of BioDelivery Sciences International, Inc. since December 2017 and...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
John Gay	Chief Financial Officer	5.3yrs	US$568.23k	0.17% $ 0.05
Scott Plesha	CEO & Director	less than a year	no data	no data
Carri Geer	Senior VP & CTO	5.3yrs	no data	no data
Sai Rangarao	Senior VP	less than a year	no data	no data
Tomoko Maeda-Chubachi	Chief Medical Officer	2.8yrs	no data	no data
Melvin Whitehead	Senior Vice President of Manufacturing Operations	less than a year	no data	no data

1.6yrs

Average Tenure

Experienced Management: 0A4P's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.

NVN Liquidation Management

Management criteria checks 0/4

Key information

Recent management updates

Insufficient new directors

Recent updates

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc.

Nasdaq To Delist the Common Stock of Novan

Novan, Inc.(OTCPK:NOVN.Q) dropped from NASDAQ Composite Index

Novan's Securities to Be Delisted from Nasdaq

Novan Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC Regarding MVLS Requirement

First quarter 2023 earnings released: US$0.54 loss per share (vs US$0.71 loss in 1Q 2022)

Novan, Inc. to Report Q1, 2023 Results on May 15, 2023

Full year 2022 earnings released: US$1.42 loss per share (vs US$1.74 loss in FY 2021)

Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (Sb206) for the Treatment of Molluscum Contagiosum

Forecast to breakeven in 2025

Novan, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Second quarter 2022 earnings released: US$0.44 loss per share (vs US$0.39 loss in 2Q 2021)

Novan Announces Publication of Positive Results from Pivotal Phase 3 Study of Berdazimer Gel, 10.3% (Sb206) in Patients with Molluscum Contagiosum in Jama Dermatology

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $14.968192 million.

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $15 million.

First quarter 2022 earnings released: US$0.71 loss per share (vs US$0.60 loss in 1Q 2021)

Novan, Inc. to Report Q1, 2022 Results on May 16, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Novan, Inc. to Report Fiscal Year 2021 Results on Feb 22, 2022

Insufficient new directors

Third quarter 2021 earnings released: US$0.34 loss per share (vs US$0.63 loss in 3Q 2020)

Novan Reports Safety Data from B-SIMPLE4 Pivotal Phase 3 Study of SB206

CEO

Tenure

Leadership Team

Average Tenure